| Idecabtagene vicleucel for relapsed/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium DK Hansen, S Sidana, LC Peres, C Colin Leitzinger, L Shune, ... Journal of Clinical Oncology 41 (11), 2087-2097, 2023 | 151 | 2023 |
| Daratumumab proves safe and highly effective in AL amyloidosis. J Khouri, A Kin, B Thapa, FJ Reu, N Bumma, CJ Samaras, HD Liu, ... British Journal of Haematology 185 (2), 2019 | 57 | 2019 |
| Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy CJ Ferreri, MAT Hildebrandt, H Hashmi, LO Shune, JP McGuirk, ... Blood cancer journal 13 (1), 117, 2023 | 45 | 2023 |
| Multiple myeloma therapy: emerging trends and challenges D Dima, D Jiang, DJ Singh, M Hasipek, HS Shah, F Ullah, J Khouri, ... Cancers 14 (17), 4082, 2022 | 37 | 2022 |
| Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study F Covut, R Ahmed, S Chawla, F Ricaurte, CJ Samaras, F Anwer, ... British Journal of Haematology 193 (6), 1213-1219, 2021 | 36 | 2021 |
| Update on the diagnosis and treatment of POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome: a review J Khouri, M Nakashima, S Wong JAMA oncology 7 (9), 1383-1391, 2021 | 34 | 2021 |
| Cisplatin-mediated upregulation of APE2 binding to MYH9 provokes mitochondrial fragmentation and acute kidney injury Y Hu, C Yang, T Amorim, M Maqbool, J Lin, C Li, C Fang, L Xue, A Kwart, ... Cancer research 81 (3), 713-723, 2021 | 32 | 2021 |
| Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM). DK Hansen, KK Patel, LC Peres, MH Kocoglu, L Shune, G Simmons, ... Journal of Clinical Oncology 41 (16_suppl), 8012-8012, 2023 | 28 | 2023 |
| Advances in delivery of ambulatory autologous stem cell transplantation for multiple myeloma J Khouri, NS Majhail Current opinion in supportive and palliative care 11 (4), 361-365, 2017 | 17 | 2017 |
| Diagnostic and treatment strategies for AL amyloidosis in an era of therapeutic innovation D Dima, S Mazzoni, F Anwer, J Khouri, C Samaras, J Valent, L Williams JCO Oncology Practice 19 (5), 265-275, 2023 | 16 | 2023 |
| Progression with clinical features is associated with worse subsequent survival in multiple myeloma R Chakraborty, HD Liu, L Rybicki, J Tomer, J Khouri, RM Dean, ... American Journal of Hematology 94 (4), 439-445, 2019 | 16 | 2019 |
| Safety and efficacy of teclistamab in patients with relapsed/refractory multiple myeloma: a real-world experience D Dima, JA Davis, N Ahmed, X Jia, A Sannareddy, H Shaikh, L Shune, ... Transplantation and cellular therapy 30 (3), 308. e1-308. e13, 2024 | 15 | 2024 |
| Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory multiple myeloma (RRMM) who have received a prior BCMA … CJ Ferreri, MAT Hildebrandt, H Hashmi, LO Shune, JP McGuirk, ... Blood 140 (Supplement 1), 1856-1858, 2022 | 15 | 2022 |
| Monoclonal gammopathy of undetermined significance: A primary care guide. J Khouri, C Samaras, J Valent, B Faiman, S Mathur, K Hamilton, ... Cleveland Clinic Journal of Medicine 86 (1), 39-46, 2019 | 15 | 2019 |
| Impact of frailty on outcomes after chimeric antigen receptor T cell therapy for patients with relapsed/refractory multiple myeloma JA Davis, D Dima, N Ahmed, S DeJarnette, J McGuirk, X Jia, S Raza, ... Transplantation and Cellular Therapy 30 (3), 298-305, 2024 | 14 | 2024 |
| Siltuximab for first-line treatment of cytokine release syndrome: a response to the national shortage of tocilizumab S Patel, D Cenin, D Corrigan, BK Hamilton, M Kalaycio, RM Sobecks, ... Blood 140 (Supplement 1), 5073-5074, 2022 | 14 | 2022 |
| Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed/refractory multiple … N Gagelmann, D Dima, M Merz, H Hashmi, N Ahmed, N Tovar, ... Journal of Clinical Oncology 42 (14), 1665-1675, 2024 | 13 | 2024 |
| Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment S Sidana, LC Peres, H Hashmi, H Hosoya, C Ferreri, J Khouri, D Dima, ... Haematologica 109 (3), 777, 2024 | 13 | 2024 |
| Management of relapsed–refractory multiple myeloma in the era of advanced therapies: evidence-based recommendations for routine clinical practice D Dima, F Ullah, S Mazzoni, L Williams, B Faiman, A Kurkowski, ... Cancers 15 (7), 2160, 2023 | 12 | 2023 |
| Incidence and management of carfilzomib-induced cardiovascular toxicity; a systematic review and meta-analysis A Latif, V Kapoor, N Lateef, MJ Ahsan, RM Usman, SU Malik, N Ahmad, ... Cardiovascular & Haematological Disorders-Drug Targets (Formerly Current …, 2021 | 12 | 2021 |
